EGFR and neoplasm: These results indicated that PD-L1 significantly promoted the proliferation of EGFR-mutant LUAD in vivo, which may be dependent on the activation of the MAPK/ERK pathway, and the pathway inhibitors could inhibit tumor growth in vivo.